Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
MOTS-c vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceVery limited comparison
At least one comparison profile is still being completed. Use the underlying compound records for the evidence currently available.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
MOTS-c is distinguished by mOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Human studies mostly measure the body's own MOTS-c; administered treatment evidence remains preclinical while a Phase 2a trial is enrolling; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
MOTS-c is distinguished in the current record by mOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Human studies mostly measure the body's own MOTS-c; administered treatment evidence remains preclinical while a Phase 2a trial is enrolling. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
MOTS-c: Profile in progress. Liraglutide: Mature human evidence.
Regulatory historyLiraglutide
MOTS-c: Investigational. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
MOTS-c
- Insulin sensitivity and prediabetes
- Metabolic homeostasis
- Exercise response
- Aging and healthspan
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
MOTS-cInvestigational
Investigational
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
MOTS-cProfile in progress
Endogenous MOTS-c changes with exercise and is associated with some human metabolic phenotypes, but no completed controlled efficacy results for administered native MOTS-c were available.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated weight-outcome summary has been editorially approved.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated diabetes-outcome summary has been editorially approved.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
MOTS-cRecord incomplete
No dedicated obstructive-sleep-apnoea outcome summary has been editorially approved.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
MOTS-cRecord incomplete
No dedicated cardiovascular-outcome summary has been editorially approved.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
MOTS-cOpen profile
Open the compound profile for approved-label information or clearly identified trial-administration records.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Very limited comparison
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether administered native MOTS-c improves meaningful human outcomes and whether repeated exposure is safe.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
MOTS-c
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.